RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MEZQUITA L
Collezione AOU San Luigi di Orbassano

Items : 6

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1?50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. in Journal for immunotherapy of cancer / J Immunother Cancer. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674.

2025
AOU San Luigi di Orbassano
AOU Novara

Wakelee H; Garassino M; Peters S; Takada K; Naqash AR; Torri V; Hejleh TA; Ferrara R; Aerts JGJV; Aboubakar Nana F; Dingemans AM; Biello F; Rogado J; Moliner L; Beninato T; Lo Russo G; Servetto A; Mezquita L; Gorría T; Minuti G; Bennati C; Tonini G; Cortinovis DL; Agustoni F; Majem M; Baena J; Macerelli M; Monnet I; O'Reilly D; et alii...

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2023 May;18(5):576-586. doi: 10.1016/j.jtho.2022.12.018. Epub 2023 Jan 13.

2023
AOU San Luigi di Orbassano

Aldea M; Marinello A; Duruisseaux M; Zrafi W; Conci N; Massa G; Metro G; Monnet I; Gomez Iranzo P; Tabbo F; Bria E; Guisier F; Vasseur D; Lindsay CR; Ponce-Aix S; Cousin S; Citarella F; Fallet V; Minatta JN; Eisert A; de Saint Basile H; Audigier-Valette C; Mezquita L; Calles A; Mountzios G; Tagliamento M; Remon Masip J; Raimbourg J; Terrisse S; et alii...

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey. in JTO clinical and research reports / JTO Clin Res Rep. 2022 Dec 15;4(1):100446. doi: 10.1016/j.jtocrr.2022.100446. eCollection 2023 Jan.

2023
AOU San Luigi di Orbassano

Novello S; Besse B; Bironzo P; De Maria A; Giaj Levra M; Remon J; Tagliamento M; Mezquita L;

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). in Cancer treatment reviews / Cancer Treat Rev. 2022 Feb;103:102335. doi: 10.1016/j.ctrv.2021.102335. Epub 2021 Dec 31.

2022
AOU San Luigi di Orbassano

Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S; Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S;

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jul;151:211-220. doi: 10.1016/j.ejca.2021.03.011. Epub 2021 May 19.

2021
AOU San Luigi di Orbassano

Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; et alii...

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2020 Jun;15(6):914-947. doi: 10.1016/j.jtho.2020.03.006. Epub 2020 Mar 14.

2020
AOU San Luigi di Orbassano

Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV;